Yiwei Xiaoyu granules mitigate spasmolytic polypeptide-expressing metaplasia-associated gastric mucosal damage by regulating WFDC2 and the miRNA-7/circRNA network

Figure 2 Validation of spasmolytic polypeptide-expressing metaplasia and spleen-stomach deficiency syndrome models through immunofluorescence and ELISA at day 15. A: Gastric mucosal immunofluorescence showing translocation of TFF2 (red) and clusterin (green) from pit regions to glandular bases in spasmolytic polypeptide-expressing metaplasia + spleen-stomach deficiency syndrome co-induction (G5) vs normal architecture (G1). Nuclei counterstained with 4’, 6-diamidino-2-phenylindole (blue). Scale bar = 200 μm; B: Creatine phosphokinase; C: Gastrin; D: Motilin. ^aP < 0.0001 vs G2, ^bP < 0.001 vs G5, ^cP < 0.05 vs G2, ^dP < 0.05 vs G3, ^eP < 0.05 vs G2, ^fP < 0.001 vs G5, ^gP < 0.01 vs G5. Data are presented as mean ± SD (n = 5 per group). Statistical analysis was performed using one-way analysis of variance followed by Tukey’s multiple-comparisons test. CPK: Creatine phosphokinase; MTL: Motilin; GAS: Gastrin.